910 Clopper Road
United States - Map
GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on using its adenovector gene delivery platform to develop a pipeline of therapeutics and vaccines in the United States. The company develops its product candidates through collaborations with various companies and organizations, including Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of various human and animal health concerns. Its lead product candidate includes CGF166, which is in Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. The company also develops vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, Enterovirus D68, and malaria, as well as vaccines against foot-and-mouth disease in the area of animal health. It has a collaboration agreement with TheraBiologics to develop cancer therapeutics. The company was founded in 1992 and is based in Gaithersburg, Maryland.
|Mr. Douglas J. Swirsky CPA, CFA,
Chief Exec. Officer, Pres, Corp. Sec. and Director
|Dr. Douglas E. Brough Ph.D.,
Chief Scientific Officer
|Dr. Bryan T. Butman Ph.D.,
Sr. VP of Devel.
|Mr. James Vincent Lambert ,
Principal Financial Officer, Principal Accounting Officer, Sr. Director of Accounting & Fin., Treasurer and Corp. Controller
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|